AR059763A2 - Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir - Google Patents

Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir

Info

Publication number
AR059763A2
AR059763A2 ARP070100928A AR059763A2 AR 059763 A2 AR059763 A2 AR 059763A2 AR P070100928 A ARP070100928 A AR P070100928A AR 059763 A2 AR059763 A2 AR 059763A2
Authority
AR
Argentina
Prior art keywords
ritonavir
crystalline
preparation
polymorm
crystal
Prior art date
Application number
Other languages
English (en)
Inventor
K Patel
Philip Bauer
Saleki Azita
H Spiwek
K Allen
B Narayanan
John Bauer
S Chemburkar
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059763(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR059763A2 publication Critical patent/AR059763A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)

Abstract

Proceso para la preparacion de la forma polimorfa cristalina 1 de ritonavir de una pureza mayor al 90%, que comprende la adicion de una solucion de la forma cristalina 2I de ritonavir a una pasta fluida de nucleos cristalinos de la forma polimorfa cristalina 1 de ritonavir en un contra solvente. Reivindicacion 1: Un proceso para la preparacion de la forma polimorfa cristalina 1 de ritonavir de una pureza mayor al 90%, caracterizado porque comprende la adicion de una solucion de la forma cristalina 2 de ritonavir a una pasta fluida de nucleos cristalinos de la forma polimorfa cristalina 1 de ritonavir en un contra solvente.
ARP070100928 1998-07-20 2007-03-06 Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir AR059763A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
AR059763A2 true AR059763A2 (es) 2008-04-30

Family

ID=26817251

Family Applications (5)

Application Number Title Priority Date Filing Date
ARP990103557 AR019431A1 (es) 1998-07-20 1999-07-20 POLIMORFO CRISTALINO DE (2S,3S,5S)-5-(N-(N-((N-METIL -N- ((2-ISOPROPIL-4-TIAZOLIL)METIL) AMINO)CARBONIL)-L-VALINIL)AMINO)-2-(N-((5-TIAZOLIL) METOXICARBONIL) AMINO-1,6-DIFENIL-3-HIDROXIHEXANO Y PROCESO PARA SU PREPARACIoN.
ARP040101329 AR044029A2 (es) 1998-07-20 2004-04-20 Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura
ARP050102703 AR049658A2 (es) 1998-07-20 2005-06-29 Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.
ARP070100929 AR059764A2 (es) 1998-07-20 2007-03-06 Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
ARP070100928 AR059763A2 (es) 1998-07-20 2007-03-06 Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ARP990103557 AR019431A1 (es) 1998-07-20 1999-07-20 POLIMORFO CRISTALINO DE (2S,3S,5S)-5-(N-(N-((N-METIL -N- ((2-ISOPROPIL-4-TIAZOLIL)METIL) AMINO)CARBONIL)-L-VALINIL)AMINO)-2-(N-((5-TIAZOLIL) METOXICARBONIL) AMINO-1,6-DIFENIL-3-HIDROXIHEXANO Y PROCESO PARA SU PREPARACIoN.
ARP040101329 AR044029A2 (es) 1998-07-20 2004-04-20 Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura
ARP050102703 AR049658A2 (es) 1998-07-20 2005-06-29 Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.
ARP070100929 AR059764A2 (es) 1998-07-20 2007-03-06 Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene

Country Status (29)

Country Link
EP (4) EP1097148B1 (es)
JP (4) JP4815050B2 (es)
KR (3) KR100853371B1 (es)
CN (5) CN1310715B (es)
AR (5) AR019431A1 (es)
AT (3) ATE534636T1 (es)
AU (1) AU768207B2 (es)
BG (4) BG65150B1 (es)
BR (1) BR9912010A (es)
CA (3) CA2674800A1 (es)
CO (1) CO5090830A1 (es)
CY (2) CY1111600T1 (es)
CZ (2) CZ307116B6 (es)
DE (2) DE69940616D1 (es)
DK (3) DK1418174T3 (es)
ES (3) ES2322759T3 (es)
HU (3) HU230150B1 (es)
ID (1) ID27996A (es)
IL (4) IL140492A0 (es)
MY (2) MY145265A (es)
NO (2) NO318385B1 (es)
NZ (2) NZ509125A (es)
PL (2) PL213978B1 (es)
PT (3) PT1418174E (es)
SI (3) SI2017269T1 (es)
SK (3) SK287586B6 (es)
TR (1) TR200100171T2 (es)
TW (3) TWI227713B (es)
WO (1) WO2000004016A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
WO2000074677A2 (en) * 1999-06-04 2000-12-14 Abbott Laboratories Improved pharmaceutical formulations
WO2002096395A1 (en) * 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
AR037797A1 (es) * 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
EP1891027A1 (en) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited Processes for the preparation of stable polymorphic form i of ritonavir
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
HUE027829T2 (en) 2012-03-07 2016-11-28 Ratiopharm Gmbh Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
ES2587559T3 (es) 2012-03-07 2016-10-25 Ratiopharm Gmbh Forma farmacéutica que comprende lopinavir y ritonavir
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
DE69305093T2 (de) * 1992-12-29 1997-04-17 Abbott Lab Inhibitoren der retroviralen protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
WO2000074677A2 (en) * 1999-06-04 2000-12-14 Abbott Laboratories Improved pharmaceutical formulations

Also Published As

Publication number Publication date
EP1097148B1 (en) 2004-03-17
CN101966180A (zh) 2011-02-09
ID27996A (id) 2001-05-03
CA2337846C (en) 2006-02-21
HU0800267D0 (en) 2008-06-30
PT1418174E (pt) 2009-06-08
NO327320B1 (no) 2009-06-08
SK287586B6 (sk) 2011-03-04
SI2017269T1 (sl) 2012-02-29
EP2017269A2 (en) 2009-01-21
EP2017269A8 (en) 2009-09-30
NZ509125A (en) 2003-02-28
DE69940616D1 (de) 2009-04-30
JP5732212B2 (ja) 2015-06-10
KR100793046B1 (ko) 2008-01-10
KR20010072003A (ko) 2001-07-31
ATE261947T1 (de) 2004-04-15
TWI271400B (en) 2007-01-21
KR20060118022A (ko) 2006-11-17
PL348033A1 (en) 2002-05-06
SK287381B6 (sk) 2010-08-09
TWI362382B (en) 2012-04-21
JP2002520410A (ja) 2002-07-09
IL140492A (en) 2010-12-30
CN1502613A (zh) 2004-06-09
DK2017269T3 (da) 2012-03-05
CN102153524A (zh) 2011-08-17
MY121765A (en) 2006-02-28
CO5090830A1 (es) 2001-10-30
MY145265A (en) 2012-01-13
ATE425974T1 (de) 2009-04-15
CZ2001203A3 (en) 2001-05-16
CN1310715A (zh) 2001-08-29
AU768207B2 (en) 2003-12-04
HU229999B1 (en) 2015-04-28
SI1418174T1 (sl) 2009-08-31
ES2322759T3 (es) 2009-06-26
CA2510949A1 (en) 2000-01-27
IL187181A0 (en) 2008-02-09
HUP0103823A2 (hu) 2002-02-28
HU227540B1 (en) 2011-08-29
AR049658A2 (es) 2006-08-23
HU0800266D0 (en) 2008-06-30
CA2337846A1 (en) 2000-01-27
EP1418174A3 (en) 2004-06-23
NO20010298L (no) 2001-01-18
JP4815050B2 (ja) 2011-11-16
AU5003799A (en) 2000-02-07
EP1418174A2 (en) 2004-05-12
PT1097148E (pt) 2004-05-31
KR20040081137A (ko) 2004-09-20
AR059764A2 (es) 2008-04-30
WO2000004016A3 (en) 2000-03-30
CN1310715B (zh) 2010-11-03
BG105197A (en) 2001-10-31
NZ522690A (en) 2004-04-30
DE69915628T2 (de) 2004-08-12
NO20010298D0 (no) 2001-01-18
TR200100171T2 (tr) 2001-05-21
EP1097148A2 (en) 2001-05-09
KR100853371B1 (ko) 2008-08-22
BG109682A (bg) 2007-03-30
SI1097148T1 (en) 2004-10-31
SK922001A3 (en) 2001-07-10
ATE534636T1 (de) 2011-12-15
IL191582A (en) 2016-02-29
DK1097148T3 (da) 2004-04-26
CA2674800A1 (en) 2000-01-27
CY1112139T1 (el) 2015-11-04
AR044029A2 (es) 2005-08-24
BG65963B1 (bg) 2010-07-30
WO2000004016A2 (en) 2000-01-27
EP2298751A3 (en) 2011-08-17
CZ298188B6 (cs) 2007-07-18
BG65150B1 (bg) 2007-04-30
EP2017269B1 (en) 2011-11-23
EP2017269A9 (en) 2009-10-14
CY1111600T1 (el) 2015-10-07
CN101259128A (zh) 2008-09-10
BG110080A (bg) 2008-11-28
ES2372990T3 (es) 2012-01-30
CZ2006533A3 (cs) 2001-05-16
EP2298751A2 (en) 2011-03-23
DK1418174T3 (da) 2009-05-18
PL213978B1 (pl) 2013-05-31
DE69915628D1 (en) 2004-04-22
BG66140B1 (bg) 2011-07-29
TW200716550A (en) 2007-05-01
PL194710B1 (pl) 2007-06-29
CA2510949C (en) 2009-11-17
KR100740796B1 (ko) 2007-07-20
JP2014074047A (ja) 2014-04-24
AR019431A1 (es) 2002-02-20
HU230150B1 (hu) 2015-09-28
IL191582A0 (en) 2008-12-29
IL187181A (en) 2009-09-01
JP2017061475A (ja) 2017-03-30
EP1418174B1 (en) 2009-03-18
IL140492A0 (en) 2002-02-10
NO20042393L (no) 2001-01-18
TWI227713B (en) 2005-02-11
HUP0103823A3 (en) 2003-05-28
PT2017269E (pt) 2011-12-20
ES2214038T3 (es) 2004-09-01
HK1037918A1 (en) 2002-02-22
HK1121155A1 (en) 2009-04-17
BR9912010A (pt) 2001-04-10
EP2017269A3 (en) 2009-06-10
SK286388B6 (sk) 2008-09-05
NO318385B1 (no) 2005-03-14
CZ307116B6 (cs) 2018-01-24
JP2010270135A (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
AR025427A1 (es) Formas farmaceuticas de administracion oral al menos parcialmente retardadas cuya sustancia activa tramadol se encuentra al menos parcialmente en forma decompuesto formado in situ con una hidrosolubilidad < o = 100 mg/ml, y procedimiento para su preparacion
RU93036185A (ru) Ингибиторы с двойным действием
NO20022989D0 (no) Middel som er anti-adhesivt i forhold til den patogene flora i huden
AR008410A1 (es) UN PROCEDIMEINTO PARA LA PREPARACIoN DE UN PRODUCTO ALIMENTICIO QUE CONTIENE PAs.
UA81657C2 (ru) Способ получения противосудорожных производных топирамата
AR059764A2 (es) Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
AR061765A2 (es) Proceso para la preparcion de sal de sodio de pravastatina en una forma cristalina
HUP0102465A3 (en) Process for the production of an aqueous monoester peroxycarboxylic acid solution, the solution obtainable by this process, and its use as disinfectant
ID28485A (id) Proses yang terus berlangsung untuk pembuatan asam n-(fosfonometil) iminodiasetat
AR029312A1 (es) Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh, procesos para su produccion, formulacion farmaceutica, y uso de estos compuestos para la elaboracion de un medicamento.
PE20060662A1 (es) Procedimiento para producir derivados de amina opticamente activos
TNSN99189A1 (fr) Procede pour la preparation de pyrazolo (4,3-d) pyrimidine-7- ones, et intermediaires pour ce procede
DK0561948T3 (da) Phosphonsyrederivater, der kan anvendes som antiinflammatoriske midler
BR9912622A (pt) ácido r- ou s-lipóico cristalino enanciomericamente puro, processo para a preparação de ácido lipóico cristalino, ácido lipóico, e, uso do mesmo
CO4970795A1 (es) Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO4340619A1 (es) Derivados cristalinos del acido n-acetil neuramico y procesos para su preparacion
AU2003269146A1 (en) Process for the preparation of sodium ferric gluconate complex in sucrose
AR027092A1 (es) Composicion para mejorar la calidad de productos de panaderia
AU2001273933A1 (en) A process for the preparation of highly crystalline sodium cefoperazone
MX2007005348A (es) Formas amorfas y polimorficas de sodio de telmisartan.
BR9906821A (pt) Composição farmacêutica e processo para melhorar a discinesia induzida por levodopa e discinesia tardia, e, uso de riluzol para a preparação de uma composição farmacêutica
PT1667655E (pt) NOVA UTILIZAÇÃO, PREPARAÇÕES FARMACjUTICAS ASSIM COMO O PROCESSO PARA A SUA PRODUÇÃO
YU74401A (sh) Postupak za dobijanje 2s-3-amino-3-arilpropionske kiseline i njenih derivata
AR047061A1 (es) Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida
HUP0301982D0 (en) Process for the preparation of high purity d-(17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime

Legal Events

Date Code Title Description
FB Suspension of granting procedure